Federico Caligaris‐Cappio

Research interests

Publications

• iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

  Blood · 2018 · https://doi.org/10.1182/blood-2017-09-806398

• Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.175

• Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1400376

• Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers

  Nature Medicine · 2014 · https://doi.org/10.1038/nm.3562

• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61381-5

• High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)61416-1

• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

  Blood · 2008 · https://doi.org/10.1182/blood-2007-06-093906

Current projects

No projects listed.